Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleIncidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernUnited States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.Influenza virus-like particles as pandemic vaccines.Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response.Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.Antivirals in seasonal and pandemic influenza--future perspectives.A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.Study design in the evaluation of breast cancer imaging technologies.Reported complications of silicone gel breast implants: an epidemiologic review.Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.Medicaid data as a resource for epidemiologic studies: strengths and limitations.A newly identified bacterium phenotypically resembling, but genetically distinct from, Legionella pneumophila: an isolate in a case of pneumonia.Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.Adamantane-resistant influenza infection during the 2004-05 season.Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors.Transmission of equine influenza virus to dogs.Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine.Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.Knowledge gaps in therapeutic and non-therapeutic research on the Middle East respiratory syndrome.Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice.Racial differences in the prevalence of intraocular lens implants in the United States.Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France).Beta-blockers and depression. Evidence against an association.Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.Mechanisms of pathogenicity of influenza A (H5N1) viruses in mice.Neurological manifestations of avian influenza viruses in mammals.WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and InnovationsThe relationship of maternal race and insurance status to prenatal ultrasound use in a national populationRelationship between mammographic and histologic features of breast tissue in women with benign biopsiesHistologic and mammographic specificity of risk factors for benign breast diseaseHow frequently are home pregnancy tests used? Results from the 1988 National Maternal and Infant Health SurveyHyperplasia and breast cancer
P50
Q21562299-E46A88E4-502A-4556-8D97-B94B325D0F27Q28275022-33BA02BC-6257-428D-B492-3645C50BCED7Q30226517-00A946FD-DCAD-436A-BCEB-CFB331AAE3E2Q30227553-CF7A45A1-A361-48EF-8BD3-71F28C94E0B3Q30230004-BFD775F8-1B71-4069-AE4C-36F4AE6D4D76Q30352927-7DF74ABA-A07D-4872-A5A6-75A09A42EE4EQ30371435-16B95503-51E1-4F91-BD60-0DF0F9DCF0FFQ30372472-1689859c-4a87-db44-60fd-08b542b0e607Q30374227-C5FED5F9-4C71-49A9-8584-7FBFE6C24A67Q30421549-A64B89BA-4A83-49A7-994B-8B85255D787AQ30425358-6551C17C-F3DE-4D1A-B1EB-702D8E67E177Q33474344-202D7494-3933-477F-9CD9-28D4A664AB4CQ34033325-569EE0BD-0379-4998-AAD8-90EA676F7F36Q34062564-5D701B4D-FAF6-4025-A30D-AED7D72B1C5CQ34576871-F5A16847-6E5B-49EB-9F4B-D02A103E6CB0Q34637724-F7E44E8E-A4EE-4AFA-AEC3-DB212119E274Q35127727-A0FB6FDE-A9EA-4B14-B6AE-6C13BE30327BQ35905583-045C2324-402C-43F4-84AD-73403B14C7EEQ36490262-D839DA26-3ED2-44D5-9F84-6ABB5C2A0E94Q36870919-9F089AB1-522C-441D-8325-45D5042D0386Q37008843-B7AF2D9F-76C7-4A08-9184-BDFBE796056FQ38346098-29E3811A-62B0-43EB-B2F5-8106FAA7200FQ40368670-5C08E3A4-5428-4E76-85FF-7F57EF85E524Q40653694-BA9D169C-A486-471E-B744-4AF95A7BAE95Q40675107-5605AF0B-021C-414B-8223-33507BD4FAA0Q40794799-52E9930F-8CB4-4DED-80BE-22312E9C19AEQ43176186-E41E5281-5CAE-45F4-930D-D8067A7EFFA6Q43923796-98945FBF-FA5F-4B9C-9698-095EC9B7E319Q44311836-387323D3-7F4D-417F-A4FA-DC008BD879CEQ45245736-23B332DF-154C-4D68-B1D0-CDD16D64AE67Q46925884-E894CA93-5F56-447C-901F-E5728F407164Q48164176-112F1EAC-7A60-4B51-BBF2-6FD4EDEE3BDAQ48164187-44067DC7-27F3-4832-96A0-CD5DCC03101EQ52803898-F2F9EF62-827A-4C18-B88A-B59AE34739FEQ64094798-BAE13D8F-D6FA-4955-8978-9CA25B7D57CEQ68096948-CAC063D8-0C45-463D-9227-A9E24B2FFC48Q68248345-6B895ED2-6569-47F0-A88B-7A337D6BB2D2Q69648483-BEF32006-6083-4887-B86C-BE6A2EE6EC8EQ70122762-4D1C3FE7-CF73-409B-BB2A-4BADE63A6098Q72799309-0164A59D-1DC5-4656-9B7D-9A820D9D4CB4
P50
description
US immunologist and US COVID19 response whistleblower
@en
inmunólogo estadounidense
@es
американський імунолог та чиновник системи охорони здоров'я, викривач
@uk
name
Rick A. Bright
@nl
Rick Bright
@en
Rick Bright
@es
Rick Bright
@it
Рік Брайт
@uk
瑞克·布萊特
@zh
type
label
Rick A. Bright
@nl
Rick Bright
@en
Rick Bright
@es
Rick Bright
@it
Рік Брайт
@uk
瑞克·布萊特
@zh
altLabel
R A Bright
@en
R. A. Bright
@en
R.A. Bright
@en
RA Bright
@en
Richard Bright
@en
Rick A Bright
@en
Rick A. Bright
@en
Rick Arthur Bright
@en
prefLabel
Rick A. Bright
@nl
Rick Bright
@en
Rick Bright
@es
Rick Bright
@it
Рік Брайт
@uk
瑞克·布萊特
@zh
P108
P69
P937
P646
P106
P108
P19
P2002
rickabright
P21
P2190
rickbright
P2381
P31
P39
P569
1966-06-07T00:00:00Z
P646
/m/030qsp8